Neural networks as valuable tools to differentiate between sesquiterpene lactones' inhibitory activity on serotonin release and on NF-κB

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1324-1332

  Wagner, Steffen ^a   Arce, Raul ^b   Murillo, Renato ^b   Terfloth, Lothar ^c   Gasteiger, Johann ^c   Merfort, Irmgard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c Molecular Networks GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SEROTONIN; SESQUITERPENE LACTONE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; DRUG MECHANISM; DRUG STRUCTURE; GENE INACTIVATION; MOLECULAR DYNAMICS; SEROTONIN RELEASE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD PLATELETS; CATTLE; ELECTRICITY; LACTONES; MODELS, MOLECULAR; NEURAL NETWORKS (COMPUTER); NF-KAPPA B; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SEROTONIN; SEROTONIN ANTAGONISTS; SESQUITERPENES;

EID: 41649110826     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701318x     Document Type: Article

References (41)

1. Schmidt, T. J. Toxic activities of sesquiterpene lactones: structural and biochemical aspects. Curr. Org. Chem. 1999, 3, 577-608.
2. Zhang, S.; Won, Y. K.; Ong, C. N.; Shen, H. M. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anti-Cancer Agents 2005, 5, 239-249.
3. Garcia-Pineres, A. J.; Castro, V.; Mora, G.; Schmidt, T. J.; Strunck, E.; Pahl, H. L.; Merfort, I. Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 2001, 276, 39713-39720.
4. Hehner, S. P.; Heinrich, M.; Bork, P. M.; Vogt, M.; Ratter, F.; Lehmann, V.; Schulze-Osthoff, K.; Droge, W.; Schmitz, M. L. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J. Biol. Chem. 1998, 273, 1288-1297.
5. Lyss, G.; Knorre, A.; Schmidt, T. J.; Pahl, H. L.; Merfort, I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J. Biol. Chem. 1998, 273, 33508-33516.
6. Maries, R. J.; Pazos-Sanou, L.; Compadre, C. M.; Pezzuto, J. M.; Bloszyk, E.; Arnason, J. T. Sesquiterpene lactones revisited. In Phytochemistry of Medicinal Plants; Arnason, J. T., Ed.; Plenum Press: New York, 1995; pp 333-356.
7. Haefner, B. The transcription factor NF-kappaB as drug target. Prog. Med. Chem. 2005, 43, 137-188.
8. Krakauer, T. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-κB. Curr. Drug Targets 2004, 3, 317-324.
9. Nakanishi, C.; Toi, M. Nuclear factor-kB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5, 297-309.
10. Pande, V.; Ramos, M. J. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem. 2005, 12, 357-374.
11. Merfort, I. Patented inhibitors (2002-2005) of the transcription factor NF-kappaB. Expert Opin. Ther. Pat. 2006, 16, 1-14.
12. Wagner, S.; Hofmann, A.; Siedle, B.; Terfloth, L.; Merfort, I.; Gasteiger, J. Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J. Med. Chem. 2006, 49, 2241-2252.
13. Silberstein, S. D.; Goadsby, P. J. Migraine: preventive treatment. Cephalalgia 2002, 22, 491-512.
14. Diener, H. C.; Pfaffenrath, V.; Schnitker, J.; Friede, M.; Henneicke-von Zepelin, H. H. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention - a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005, 25, 1031-1041.
15. Groenewegen, W. A.; Knight, D. W.; Heptinstall, S. Compounds extracted from feverfew that have anti-secretory activity contain an alpha-methylene butyrolactone unit. J. Pharm. Pharmacol. 1986, 38, 709-712.
16. Schroder, H.; Losche, W.; Strobach, H.; Leven, W.; Willuhn, G.; Till, U.; Schror, K. Helenalin and 11 alpha,13-dihydrohelenalin, two constituents from Arnica montana L., inhibit human platelet function via thiol-dependent pathways. Thromb. Res. 1990, 57, 839-845.
17. Schmidt, T. J. Helenanolide-type sesquiterpene lactones. III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorg. Med. Chem. 1997, 5, 645-653.
18. Garcia-Pineres, A. J.; Lindenmeyer, M. T.; Merfort, I. Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci. 2004, 75, 841-856.
19. Zupan, J.; Gasteiger, J. Neural Networks in Chemistry and Drug Design; Wiley-VCH: Weinheim, 1999.
20. Kohonen, T. Self-organized formation of topologically correct feature maps. Biol. Cybern. 1982, 43, 59-69.
21. Kohonen, T. Analysis of a simple self-organizing process. Biol. Cybern. 1982, 44, 135-140.
22. Guha, R.; Serra, J. R.; Jurs, P. C. Generation of QSAR sets with a self-organizing map. J. Mol. Graph. Model. 2004, 23, 1-14.
23. Lindenmeyer, M. T.; Hrenn, A.; Kern, C.; Castro, V.; Murillo, R.; Muller, S.; Laufer, S.; Schulte-Monting, J.; Siedle, B.; Merfort, I. Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells. Bioorg. Med. Chem. 2006, 14, 2487-2497.
24. Descriptor calculation package ADRIANA.Code is available from Molecular Networks GmbH, Erlangen, Germany (http://www.molecular-networks.com, accessed January, 2008).
25. Siedle, B.; Garcia-Pineres, A. J.; Murillo, R.; Schulte-Monting, J.; Castro, V.; Rungeler, P.; Klaas, C. A.; Da Costa, F. B.; Kisiel, W.; Merfort, I. Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J. Med. Chem. 2004, 47, 6042-6054.
26. Luo, Q.; Darsey, J. A.; Compadre, C. M.; Mitra, S. K. Prediction of potential antimigraine activity using artificial neural networks. J. Arkansas Acad. Sci. 1997, 51, 131-134.
27. Kupchan, S. M.; Eakin, M. A.; Thomas, A. M. Tumor inhibitors. 69. Structure-cytotoxicity relationships among the sesquiterpene lactones. J. Med. Chem. 1971, 14, 1147-1152.
28. Huang, X.; Zheng, F.; Chen, X.; Crooks, P. A.; Dwoskin, L. P.; Zhan, C. G. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. J. Med. Chem. 2006, 49, 7661-7674.
29. Mezey, P. G. Molecular surfaces. In Reviews in Computational Chemistry; Lipkowitz, K. B., Boyd, D. B., Eds.; VCH Publisher: New York, Weinheim, Cambridge, 1990; pp 265-294.
30. Teckentrup, A.; Briem, H.; Gasteiger, J. Mining high-throughput screening data of combinatorial libraries: Development of a filter to distinguish hits from nonhits. J. Chem. Inf. Comput. Sci. 2004, 44, 626-634.
31. Marles, R. J.; Kaminski, J.; Arnason, J. T.; Pazos-Sanou, L.; Heptinstall, S.; Fischer, N. H.; Crompton, C. W.; Kindack, D. G.; Awang, D. V. A bioassay for inhibition of serotonin release from bovine platelets. J. Nat. Prod. 1992, 55, 1044-1056.
32. 3D Structure Generator CORINA is available from Molecular Networks GmbH, Erlangen, Germany (http://www.molecular-networks.com, accessed January, 2008).
33. Rungeler, P.; Brecht, V.; Tamayo-Castillo, G.; Merfort, I. Germacranolides from Mikania guaco. Phytochemistry 2001, 56, 475-489.
34. Hemmer, M. C.; Steinhauer, V.; Gasteiger, J. Deriving the 3D structure of organic molecules from their infrared spectra. Vib. Spectrosc. 1999, 19, 151-164.
35. Hemmer, M. C.; Gasteiger, J. Prediction of three-dimensional molecular structures using information from infrared spectra. Anal. Chim. Acta 2000, 420, 145-154.
36. Gasteiger, J.; Engel, T. Chemoinformatics: A Textbook; Wiley-VCH: Weinheim, 2003.
37. Mazzatorta, P.; Vracko, M.; Jezierska, A.; Benfenati, E. Modeling toxicity by using supervised Kohonen neural networks. J. Chem. Inf. Comput. Sci. 2003, 43, 485-492.
38. Neural networks package SONNIA is available from Molecular Networks GmbH, Erlangen, Germany (http://www.molecular-networks.com, accessed January, 2008).
39. Anzali, S.; Gasteiger, J.; Holzgrabe, U.; Polanski, J.; Sadowski, J.; Teckentrup, A.; Wagener, M. The use of self-organizing neural networks in drug design. In 3D QSAR in Drug Design; Kubinyi, H., Folkers, G., Martin, Y. C., Eds.; Kluwer/ESCOM: Dordrecht, 1998; Vol. 2, pp 273-299.
40. SONNIA. User Manual, Version 1.0; Molecular Networks GmbH: Erlangen, Germany. http://www.molecular-networks.com/software/sonnia/ sonnia_manual.pdf, accessed January, 2008.
41. Spycher, S.; Pellegrini, E.; Gasteiger, J. Use of structure descriptors to discriminate between modes of toxic action of phenols. J. Chem. Inf. Model. 2005, 45, 200-208.